GLMD logo

Galmed Pharmaceuticals (GLMD) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

13 March 2014

Indexes:

Not included

Description:

Galmed Pharmaceuticals (GLMD) is a biopharmaceutical company focused on developing treatments for liver diseases, particularly non-alcoholic steatohepatitis (NASH). They aim to improve patient outcomes through innovative therapies, with a strong emphasis on research and clinical trials to bring new medications to market.

Events Calendar

Earnings

Next earnings date:

Nov 28, 2024

Recent quarterly earnings:

Aug 28, 2024

Recent annual earnings:

May 02, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Aug 30, 2024

Analyst ratings

Recent major analysts updates

24 July '23 Maxim Group
Buy
08 Aug '22 Maxim Group
Hold
08 Aug '22 Canaccord Genuity
Hold
18 May '22 Raymond James
Market Perform
03 May '22 Raymond James
Outperform
03 May '22 HC Wainwright & Co.
Neutral
17 May '21 Canaccord Genuity
Buy
19 Mar '21 HC Wainwright & Co.
Buy
08 Jan '21 Raymond James
Outperform
25 Nov '20 Canaccord Genuity
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
GLMD
prnewswire.com25 September 2024

The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH) Data is confirmed using 3 objective measurements; NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis Continuous histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology TEL AVIV, Israel , Sept. 25, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.

Galmed Pharma Surges 400%: What's Behind the Explosion?
Galmed Pharma Surges 400%: What's Behind the Explosion?
Galmed Pharma Surges 400%: What's Behind the Explosion?
GLMD
marketbeat.com17 September 2024

Galmed Pharmaceuticals NASDAQ: GLMD, a little-known biotech stock, has become the center of attention as its shares have skyrocketed close to 400%. By 2 pm, the stock had traded over 80 million shares, a monumental leap from its average daily volume of just 75,000.

Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?
Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?
Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?
GLMD
InvestorPlace13 July 2023

Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is on the move Thursday after the company priced a public offering of its shares. Galmed Pharmaceuticals intends to offer up 6,578,947 shares of GLMD stock at a price of $2.28 per share.

Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?
Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?
Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?
GLMD
InvestorPlace05 May 2023

Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is gaining on Friday after the company announced an investment agreement with OnKai . That agreement has Galmed Pharmaceuticals making a $1.5 million equity investment in OnKai.

FAQ

  • What is the primary business of Galmed Pharmaceuticals?
  • What is the ticker symbol for Galmed Pharmaceuticals?
  • Does Galmed Pharmaceuticals pay dividends?
  • What sector is Galmed Pharmaceuticals in?
  • What industry is Galmed Pharmaceuticals in?
  • What country is Galmed Pharmaceuticals based in?
  • When did Galmed Pharmaceuticals go public?
  • Is Galmed Pharmaceuticals in the S&P 500?
  • Is Galmed Pharmaceuticals in the NASDAQ 100?
  • Is Galmed Pharmaceuticals in the Dow Jones?
  • When was Galmed Pharmaceuticals's last earnings report?
  • When does Galmed Pharmaceuticals report earnings?
  • Should I buy Galmed Pharmaceuticals stock now?

What is the primary business of Galmed Pharmaceuticals?

Galmed Pharmaceuticals (GLMD) is a biopharmaceutical company focused on developing treatments for liver diseases, particularly non-alcoholic steatohepatitis (NASH). They aim to improve patient outcomes through innovative therapies, with a strong emphasis on research and clinical trials to bring new medications to market.

What is the ticker symbol for Galmed Pharmaceuticals?

The ticker symbol for Galmed Pharmaceuticals is NASDAQ:GLMD

Does Galmed Pharmaceuticals pay dividends?

No, Galmed Pharmaceuticals does not pay dividends

What sector is Galmed Pharmaceuticals in?

Galmed Pharmaceuticals is in the Healthcare sector

What industry is Galmed Pharmaceuticals in?

Galmed Pharmaceuticals is in the Biotechnology industry

What country is Galmed Pharmaceuticals based in?

Galmed Pharmaceuticals is headquartered in Israel

When did Galmed Pharmaceuticals go public?

Galmed Pharmaceuticals's initial public offering (IPO) was on 13 March 2014

Is Galmed Pharmaceuticals in the S&P 500?

No, Galmed Pharmaceuticals is not included in the S&P 500 index

Is Galmed Pharmaceuticals in the NASDAQ 100?

No, Galmed Pharmaceuticals is not included in the NASDAQ 100 index

Is Galmed Pharmaceuticals in the Dow Jones?

No, Galmed Pharmaceuticals is not included in the Dow Jones index

When was Galmed Pharmaceuticals's last earnings report?

Galmed Pharmaceuticals's most recent earnings report was on 28 August 2024

When does Galmed Pharmaceuticals report earnings?

The next expected earnings date for Galmed Pharmaceuticals is 28 November 2024

Should I buy Galmed Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions